CL2020000879A1 - Análogos de saponina de triterpeno. - Google Patents

Análogos de saponina de triterpeno.

Info

Publication number
CL2020000879A1
CL2020000879A1 CL2020000879A CL2020000879A CL2020000879A1 CL 2020000879 A1 CL2020000879 A1 CL 2020000879A1 CL 2020000879 A CL2020000879 A CL 2020000879A CL 2020000879 A CL2020000879 A CL 2020000879A CL 2020000879 A1 CL2020000879 A1 CL 2020000879A1
Authority
CL
Chile
Prior art keywords
triterpene saponin
saponin analogs
analogs
compounds
application
Prior art date
Application number
CL2020000879A
Other languages
English (en)
Inventor
Jeffrey Gardner
J Tyler Martin
Original Assignee
Adjuvance Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adjuvance Tech Inc filed Critical Adjuvance Tech Inc
Publication of CL2020000879A1 publication Critical patent/CL2020000879A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE SOLICITUD SE REFIERE A ADYUVANTES DERIVADOS DE GLUCÓSIDO DE SAPONINA TRITERPÉNICA, A LAS SÍNTESIS DE LAS MISMAS Y A LOS INTERMEDIARIOS DE ELLAS. LA SOLICITUD TAMBIÉN PROPORCIONA COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN COMPUESTOS DE LA PRESENTE INVENCIÓN Y MÉTODOS PARA USAR DICHOS COMPUESTOS O COMPOSICIONES EN EL TRATAMIENTO DE Y EN LA INMUNIZACIÓN PARA ENFERMEDADES INFECCIOSAS Y CÁNCERES.
CL2020000879A 2017-10-16 2020-04-01 Análogos de saponina de triterpeno. CL2020000879A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762572857P 2017-10-16 2017-10-16
US201762573501P 2017-10-17 2017-10-17

Publications (1)

Publication Number Publication Date
CL2020000879A1 true CL2020000879A1 (es) 2020-10-02

Family

ID=66173854

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020000879A CL2020000879A1 (es) 2017-10-16 2020-04-01 Análogos de saponina de triterpeno.

Country Status (11)

Country Link
US (2) US11324821B2 (es)
EP (1) EP3697802A4 (es)
JP (2) JP2020536946A (es)
KR (1) KR20200098476A (es)
CN (1) CN111212846B (es)
AU (1) AU2018350887A1 (es)
CA (1) CA3075822A1 (es)
CL (1) CL2020000879A1 (es)
IL (1) IL273691A (es)
SG (1) SG11202001826YA (es)
WO (1) WO2019079160A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202106403QA (en) * 2014-05-30 2021-07-29 Memorial Sloan Kettering Cancer Center Minimal saponin analogues, synthesis and use thereof
KR20200098476A (ko) * 2017-10-16 2020-08-20 아쥬반스 테크놀로지스 인코포레이티드 트리테르펜 사포닌 유사체
AU2021276401A1 (en) 2020-05-19 2022-12-15 Othair Prothena Limited Multi-epitope vaccine for the treatment of Alzheimer's disease
US20230263886A1 (en) * 2020-06-18 2023-08-24 Adjuvance Technologies, Inc. Vaccines, vaccine priming, and antigen dose sparing
JP2023542141A (ja) 2020-09-15 2023-10-05 ザ ユニバーシティー オブ モンタナ 繊維状バクテリオファージを標的化する組成物および方法
WO2023081505A1 (en) * 2021-11-08 2023-05-11 Adjuvance Technologies, Inc. Adjuvant compounds and formulations
EP4190359A1 (en) 2021-12-03 2023-06-07 Asociación Centro de Investigación Cooperativa en Biociencias - CIC bioGUNE Saponin-based adjuvants and vaccines
WO2023139145A1 (en) 2022-01-19 2023-07-27 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune Saponin-based adjuvants and vaccines

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231112A (en) 1984-04-12 1993-07-27 The Liposome Company, Inc. Compositions containing tris salt of cholesterol hemisuccinate and antifungal
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US4684479A (en) 1985-08-14 1987-08-04 Arrigo Joseph S D Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures
US6759057B1 (en) 1986-06-12 2004-07-06 The Liposome Company, Inc. Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs
IE60901B1 (en) 1986-08-21 1994-08-24 Vestar Inc Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics
US6406713B1 (en) 1987-03-05 2002-06-18 The Liposome Company, Inc. Methods of preparing low-toxicity drug-lipid complexes
AU598958B2 (en) 1987-11-12 1990-07-05 Vestar, Inc. Improved amphotericin b liposome preparation
US5215680A (en) 1990-07-10 1993-06-01 Cavitation-Control Technology, Inc. Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles
ATE252372T1 (de) 1996-08-23 2003-11-15 Sequus Pharm Inc Liposome enthaltend cisplatin
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
EP0932390A1 (en) 1996-10-11 1999-08-04 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
WO1998016199A1 (en) 1996-10-15 1998-04-23 The Liposome Company, Inc. N-acyl phosphatidylethanolamine-mediated liposomal drug delivery
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
US6262029B1 (en) 1998-08-14 2001-07-17 Galenica Pharmaceuticals, Inc. Chemically modified saponins and the use thereof as adjuvants
WO2001015727A2 (en) 1999-09-02 2001-03-08 Antigenics Inc. Compositions of immunostimulatory polymers and saponin adjuvants and uses thereof
GB0401239D0 (en) 2004-01-21 2004-02-25 Molecularnature Ltd Adjuvant compositions
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
JP5331105B2 (ja) * 2007-05-24 2013-10-30 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 凍結乾燥抗原組成物
JP2011507816A (ja) 2007-12-21 2011-03-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム マラリア用ワクチン
EP3868771A1 (en) 2008-04-08 2021-08-25 Sloan-Kettering Institute for Cancer Research Triterpene saponins, methods of synthesis, and uses thereof
WO2009127676A1 (en) 2008-04-16 2009-10-22 Glaxosmithkline Biologicals S.A. Vaccine
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
SG178954A1 (en) 2009-09-02 2012-04-27 Novartis Ag Immunogenic compositions including tlr activity modulators
US20130309273A1 (en) 2012-05-17 2013-11-21 Kimberly Hassett Thermostable Vaccine Compositions and Methods of Preparing Same
EA201391456A1 (ru) * 2011-05-17 2014-05-30 Глаксосмитклайн Байолоджикалс С.А. ВАКЦИНА ПРОТИВ Streptococcus pneumoniae
WO2014124860A1 (en) 2013-02-14 2014-08-21 Boehringer Ingelheim International Gmbh Specific pde4b-inhibitors for the treatment of diabetes mellitus
US20150037374A1 (en) 2013-07-31 2015-02-05 Csl Limited Anti-tumor compositions and uses thereof
SG10202106403QA (en) 2014-05-30 2021-07-29 Memorial Sloan Kettering Cancer Center Minimal saponin analogues, synthesis and use thereof
EP3370730A4 (en) 2015-11-06 2019-07-31 Adjuvance Technologies, Inc. TRITERPENIC SAPONIN ANALOGS
US11629162B2 (en) 2015-12-17 2023-04-18 Memorial Sloan-Kettering Cancer Center Triterpene saponin variants, methods of synthesis and use thereof
KR20190137808A (ko) 2017-04-13 2019-12-11 아쥬반스 테크놀로지스 인코포레이티드 트리테르펜 사포닌, 중간체 및 보조제 배합물
US20210283248A1 (en) 2017-04-25 2021-09-16 Adjuvance Technologies, Inc. Triterpene saponin analogues
US20200164065A1 (en) 2017-04-25 2020-05-28 Adjuvance Technologies, Inc. Triterpene saponin analogues
KR20200098476A (ko) * 2017-10-16 2020-08-20 아쥬반스 테크놀로지스 인코포레이티드 트리테르펜 사포닌 유사체

Also Published As

Publication number Publication date
US20200261571A1 (en) 2020-08-20
AU2018350887A1 (en) 2020-03-05
IL273691A (en) 2020-05-31
WO2019079160A1 (en) 2019-04-25
CN111212846A (zh) 2020-05-29
SG11202001826YA (en) 2020-03-30
EP3697802A4 (en) 2021-11-24
JP2022191329A (ja) 2022-12-27
JP2020536946A (ja) 2020-12-17
US20220184207A1 (en) 2022-06-16
CN111212846B (zh) 2023-05-26
KR20200098476A (ko) 2020-08-20
EP3697802A1 (en) 2020-08-26
CA3075822A1 (en) 2019-04-25
US11324821B2 (en) 2022-05-10

Similar Documents

Publication Publication Date Title
CL2020000879A1 (es) Análogos de saponina de triterpeno.
CL2018001192A1 (es) Análogos de saponina triterpeno
CL2019002876A1 (es) Síntesis de triterpeno-saponina, intermediarios y combinaciones adyuvantes.
CL2019003064A1 (es) Análogos de triterperno saponina.
CL2019001744A1 (es) Derivados de benzoxazol como inmunomoduladores.
CL2019000221A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1.
ECSP19015192A (es) Composiciones y métodos de inhibir masp-3 para el tratamiento de diversas enfermedades y trastornos
CL2018000952A1 (es) Compuestos útiles como inmunomoduladores
CL2017002606A1 (es) Inhibidor de bromodominio
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
CO2018002060A2 (es) Compuestos farmacéuticos
GT201600147A (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2
CL2019000266A1 (es) Composición de cannabis.
PE20181303A1 (es) Compuestos que inhiben eif4a y metodos relacionados a los mismos
CL2020000422A1 (es) Composiciones de glp-1 y sus usos.
CO2020007018A2 (es) Proceso para preparar tapinarof
CL2016003048A1 (es) Analogos de panonina minimas sintesis y uso de los mismos.
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
CL2021001395A1 (es) Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades.
GT201700188A (es) Anticuerpos contra tau y sus usos
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
BR112017012381A2 (pt) imunoterapia para doença angiogênica
ECSP19057403A (es) Usos terapéuticos de un polvo de insectos
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
BR112019021867A2 (pt) Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenil